SNCA and Alzheimer disease: As seen in Alzheimer’s disease (AD), with the advent of amyloid PET imaging [8,9], the development of molecular imaging techniques that allow for the in vivo visualization of α-synuclein could greatly enhance research efforts and serve as a valuable adjunct in clinical care by enabling earlier diagnosis and more precise monitoring of disease progression in patients with syuncleinopathies and other Parkinsonian syndromes.